A study looking at ovarian cancer screening for women at high risk - The United Kingdom Familial Ovarian Cancer Screening Study (UK FOCSS)

Cancer type:

Breast cancer
Ovarian cancer





This study looked at screening women who are at a high risk of developing ovarian cancer. This may be because they have a family history of ovarian or breast cancer, or they have family members with a known genetic change such as BRCA 1 or BRCA 2. This trial was supported by Cancer Research UK.

When we talk about ovarian cancer in this summary we mean ovarian cancer, fallopian tube cancer or primary peritoneal cancer. All three have similar risk factors, symptoms and treatments.

Over 7,000 women are diagnosed with ovarian cancer in the UK every year. We know that women who have 2 or more close relatives with ovarian cancer or breast cancer may have a higher risk of developing ovarian cancer themselves.

Some women at high risk of developing ovarian cancer have screening. But we don't know yet if screening is helpful or not.

The aim of this trial was to find out whether screening tests can pick up ovarian cancer at an early stage, before it causes symptoms and when treatment is more likely to be successful.

Summary of results

The research team found that most of the cancers diagnosed as a result of yearly screening were not early stage, and that it is important not to delay screening or treatment.

This trial recruited 3,563 women with an increased risk of developing ovarian cancer. They had an increased risk either because they had a strong family history, or because they had a change (alteration) in a gene such as BRCA 1 or 2.

In Part 1 of the trial, women had an ultrasound scan and a CA125 blood test once a year. The results here are about Part 1.

In total, 37 women were diagnosed with ovarian, fallopian tube or primary peritoneal cancer.

The research team found that the gap between screening tests made a difference to the stage of cancer at diagnosis. The results showed that women who had longer than a year between screening tests were more likely to be diagnosed with a more advanced cancer.

The research team think if it may be better to do screening tests more often, so they set up Part 2 of the trial in 2007 to try and find out. The women in Part 2 of this trial have screening tests every 4 months instead of once a year. We don’t yet know how well this will work. The research team are now following the women in this part of the trial and plan to publish results in the future.

The trial team concluded that screening once a year may not be often enough to detect early stage ovarian cancer in women at high risk of developing the disease, and that it is important not to delay further screening or treatment.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Ian Jacobs

Supported by

Cancer Research UK
NHS Research and Development
NIHR Clinical Research Network: Cancer
National Institutes of Health (NIH)
The Eve Appeal

Other information

This is Cancer Research UK trial number CRUK/00/005.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 1083

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think